Lmod2 Knockout cell line (C2C12)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

LMOD2 (leiomodin 2)encodes an actin-binding protein that regulates actin filament polymerization and sarcomere organization in striated muscle. By controlling thin filament assembly and stability, LMOD2 contributes to myofibril architecture and muscle contractile function. It is widely studied in skeletal and cardiac muscle biology, sarcomere assembly, and cytoskeletal organization.

The C2C12 cell line is a highly dynamic, rapidly proliferating subclone produced by H. Blau et al. from the parental mouse myoblast line originally established by D. Yaffe and O. Saxel from the normal adult leg muscle of the C3H mouse strain. Universally recognized as a premier in vitro model for studying myogenesis, skeletal muscle development, and cellular differentiation kinetics, this adherent line possesses exceptional multi-lineage plasticity. When incubated with horse serum at high confluency, C2C12 cells differentiate rapidly to form extensive, contracting multinucleated myotubes that express characteristic muscle-specific proteins; conversely, treating the culture with bone morphogenetic protein 2 (BMP-2) successfully redirects their lineage to differentiate into functional osteoblasts. To preserve this high-differentiation potency and prevent spontaneous fusion, cultures must be proactively seeded at a low density and strictly maintained at a sub-confluent state below 80% maximum density.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.